Ms. Claire Stawnyczy reports

HEALTH CANADA ENDORSES LOPHOPHORA WILLIAMSII, ELEVATING LOPHOS HOLDINGS INC. AS A LEADER IN NATURAL HEALTH INNOVATION

Lophos Holdings Inc. has made a significant stride in the natural health sector. Health Canada's recent recognition of lophophora williamsii as a natural health product ingredient marks a pivotal moment in the therapeutic use of psychoactive plants, reinforcing Lophos's position at the forefront of this innovative field.

Groundbreaking achievement

Lophos Pharmaceuticals Corp., a wholly owned subsidiary of Lophos Holdings, operates from Napanee, Ont., focusing on the cultivation and production of lophophora williamsii. This decision by Health Canada not only highlights the therapeutic potential of lophophora williamsii but also demonstrates Lophos's commitment to integrating traditional wisdom with modern science to revolutionize natural health products.

Chief executive officer's vision

Claire Stawnyczy, chief executive officer of Lophos, shared her excitement, stating: "Health Canada's recognition is a validation of our commitment and a significant achievement for the industry. It opens avenues for novel and innovative applications of psychoactive cacti in promoting human well-being." She added, "Being at the forefront of Lophophora williamsii cultivation, we are eager to provide our ethically cultivated cacti to drive innovation in natural health products."

The future landscape

Health Canada's decision marks a shift in the perception of psychoactive plants, blending traditional knowledge with cutting-edge science. Lophos stands at the intersection of this evolution, poised to unlock the full potential of Lophophora williamsii.

Strategic highlights

Health Canada recognition: The therapeutic promise of lophophora williamsii is validated with this approval and listing in the natural health product ingredient.

Controlled substance dealers licence: Ensures responsible cultivation and production at Lophos's Napanee facility.

Innovation in natural health: Lophos leads the way in cultivating sustainable and effective natural health solutions.

Lophos facility highlights:

• CSDL licensed facility;
• Authorized to produce mescaline, psilocin and psilocybin;
• Authorized for the sale, transportation and distribution of controlled substances, including mescaline, psilocin and psilocybin, DMT, LSD, MDMA and ketamine;
• Privately owned, state-of-the-art facility spanning 10,000 square feet, with 4,000 square feet of dedicated cultivation space.

About Lophos Holdings Inc.

Lophos Pharmaceuticals, a key subsidiary of Lophos Holdings, is at the forefront of peyote cactus cultivation, research and sale.

We seek Safe Harbor.